Skip to main content

ADVERTISEMENT

Hongnan Mo, MD

Hongnan Mo, MD
Conference Coverage
12/07/2023
Hongnan Mo, MD, discussed results from a phase 2 study comparing metronomic chemotherapy plus PD-1 blockade to combined conventional chemotherapy plus immune checkpoint blockade.
Hongnan Mo, MD, discussed results from a phase 2 study comparing metronomic chemotherapy plus PD-1 blockade to combined conventional chemotherapy plus immune checkpoint blockade.
Hongnan Mo, MD, discussed...
12/07/2023
Oncology